Compare

Palatin Technologies Inc vs Tonix Pharmaceuticals Holding Corp. vs Evommune, Inc. vs CV Sciences, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearPalatin Technologies Inc
PTN
Tonix Pharmaceuticals Holding Corp.
TNXP
Evommune, Inc.
EVMN
CV Sciences, Inc.
CVSI
Year ended2026-06-302025-12-312025-12-312025-12-31
Revenue$13.19M$13.11M$13.00M$13.79M
Revenue growth (YoY)n/a+29.8%+85.7%-12.2%
Gross marginn/a49.3% (computed)n/a49.0%
Operating margin-65.7%-959.1%-623.6%-3.4%
Net margin-63.5%-946.2%-529.8%-6.9%
Net income-$8.38M-$124.02M-$68.87M-$958.0K
EPS (Diluted)-$2.96-$14.57-$11.22-$0.01
Operating cash flow-$13.53M-$99.84M-$76.44M-$407.0K
Free cash flow-$13.58M-$103.21M-$76.68M-$516.0K
Cash & equivalents$7.49M$207.64M$44.06Mn/a
Total assets$8.52M$277.17M$224.95M$6.96M
Total liabilities$1.84M$32.02M$19.38M$5.49M
Shareholders' equity$6.69M$245.15M$205.57M$1.47M
Return on year-end equity-125.3%-50.6%-33.5%-65.3%
Shares outstanding1.78M12.79M31.52M184.26M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearPalatin Technologies IncTonix Pharmaceuticals Holding Corp.Evommune, Inc.CV Sciences, Inc.
Latest$13.19M
Ended 2026-06-30
$13.11M
Ended 2025-12-31
$13.00M
Ended 2025-12-31
$13.79M
Ended 2025-12-31
1 year earliern/a$10.09M
Ended 2024-12-31
$7.00M
Ended 2024-12-31
$15.71M
Ended 2024-12-31
2 years earliern/a$7.77M
Ended 2023-12-31
n/a$16.00M
Ended 2023-12-31
3 years earliern/an/an/a$16.20M
Ended 2022-12-31
4 years earliern/an/an/a$20.05M
Ended 2021-12-31